Watson Pharmaceuticals Invests in $15M New Jersey Expansion
05/27/2010
"Over the past year, we have outgrown our current administrative headquarters site, as our U.S. and global business has rapidly grown," said Paul Biscaro, Watson president and CEO. "This new facility will ensure that we have a single location for the leadership and shared services functions that are driving our global growth."
New Jersey's Business Employment Incentive Program (BEIP) has extended Watson a grant of approximately $7.3 million over the next 10 years from the state's Economic Development Authority. It has also been approved for a $290,000 Business Retention and Relocation Assistance Grant (BRRAG) to retain 200 jobs in New Jersey.
Watson was the country's third largest producer of generic drugs in 2009 based on prescriptions dispensed. It specializes in drugs for urology and women's health.
Project Announcements
South Korea-Based Seoyon E-HWA Plans Chatham County, Georgia, Manufacturing Plant
02/02/2023
Bottling Company International Plans Morrison, Tennessee, Operations Complex
02/01/2023
Engineered BioPharmaceuticals Expands Danville, Virginia, Operations
02/01/2023
Ancra Cargo Establishes Hebron, Kentucky, Headquarters
01/31/2023
Pace Industries Expands Jackson, Tennessee, Operations
01/31/2023
Green Georgia Plans Thomaston, Georgia, Headquarters-Manufacturing Campus
01/31/2023
Most Read
-
2022 Top States for Doing Business Provide an Environment for Business Growth
Q3 2022
-
Location Factors in the EV Industry — “Mission Critical” or “Nice to Have”?
2022 Auto/Aero Site Guide
-
Three Big Challenges Facing the Food & Beverage Industry
Q4 2022
-
How Are Economic Developers Partnering to Solve Workforce Challenges?
Q1 2023
-
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
Q1 2022
-
Fixing the Supply Chain with AI and Robotics
Q4 2022
-
18th Annual Consultants Survey: Access to Major Markets and Skilled Labor Are Clients’ Primary Concerns
Q1 2022